New procedure could replace pills for Hormone-Driven high blood pressure

NCT ID NCT05561361

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a procedure called superselective adrenal artery embolization can improve blood vessel function in people with primary aldosteronism, a condition where the adrenal glands make too much of the hormone aldosterone, causing high blood pressure. The procedure involves injecting a substance to block part of the adrenal gland, reducing hormone production. Researchers will compare this to standard treatment with the drug spironolactone in 200 adults aged 18-75.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

superselective adrenal artery embolization (a procedure that blocks part of the adrenal gland to reduce hormone secretion)

What this could lead to

If successful, this procedure could offer a less invasive alternative to long-term medication for controlling high blood pressure caused by primary aldosteronism.

What could go wrong

This is a relatively early study with 200 participants, and the procedure carries risks like bleeding or damage to the adrenal gland. It may not prove better than standard drug therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY ALDOSTERONISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••